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ABSTRACT
Background: The use of quantitative sensory testing (QST) in multicenter studies has been
quite limited, due in part to lack of standardized procedures among centers.
Aim: The aim of this study was to assess the application of the capsaicin pain model as a
surrogate experimental human model of neuropathic pain in different centers and verify the
variation in reports of QST measures across centers.
Methods: A multicenter study conducted by the Quebec Pain Research Network in six
laboratories allowed the evaluation of nine QST parameters in 60 healthy subjects treated
with topical capsaicin to model unilateral pain and allodynia. The same measurements (with-
out capsaicin) were taken in 20 patients with chronic neuropathic pain recruited from an
independent pain clinic.
Results: Results revealed that six parameters detected a significant difference between the
capsaicin-treated and the control skin areas: (1) cold detection threshold (CDT) and (2) cold
pain threshold (CPT) are lower on the capsaicin-treated side, indicating a decreased in cold
sensitivity; (3) heat pain threshold (HPT) was lower on the capsaicin-treated side in healthy
subjects, suggesting an increased heat pain sensitivity; (4) dynamic mechanical allodynia
(DMA); (5) mechanical pain after two stimulations (MPS2); and (6) mechanical pain summa-
tion after ten stimulations (MPS10), are increased on the capsaicin-treated side, suggesting
an increased in mechanical pain (P < 0.002). CDT, CPT and HPT showed comparable effects
across all six centers, with CPT and HPT demonstrating the best sensitivity. Data from the
patients showed significant difference between affected and unaffected body side but only
with CDT.
Conclusion: These results provide further support for the application of QST in multicenter
studies examining normal and pathological pain responses.
RÉSUMÉ
Contexte: L’utilisation de tests sensoriels quantitatifs (QST) dans les études multicentriques est
limitée, en partie à cause de l’absence de procédures normalisées au sein des centres.
But: évaluer l’application du modèle de la douleur traitée par capsaïcine en tant que
modèle expérimental humain de substitution pour la douleur neuropathique dans
différents centres et vérifier les variations dans les mesures des tests sensoriels quantitatifs
entre les centres.
Méthodes: Une étude multicentrique menée par le Réseau québécois de recherche sur la
douleur dans six laboratoires a permis d’évaluer neuf paramètres de tests sensoriels quantita-
tifs chez 60 sujets en bonne santé traités par capsaïcine topique afin de modéliser la douleur
unilatérale et l’allodynie. Les mêmes mesures (sans capsaïcine) ont été prises chez 20 patients
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atteints de douleur neuropathique chronique recrutés dans une clinique de la douleur
indépendante.
Résultats: Les résultats ont révélé une différence significative entre la zone de peau traitée à la
capsaïcine et la zone contrôle pour six paramètres : 1) le seuil de détection du froid (CTF) et 2)
le seuil de perception de la douleur causée par le froid (CPT) étaient plus bas sur le côté traité
par capsaïcine chez les sujets en bonne santé, ce qui indique une diminution de la sensibilité
au froid, 3) Le seuil de perception de la douleur causée par la chaleur (HPT) était plus bas sur le
côté traité par capsaïcine chez les sujets en bonne santé, ce qui suggère une augmentation de
la sensibilité à la douleur causée par la chaleur; 4) l’allodynie mécanique dynamique (DMA), 5)
la douleur mécanique après deux stimulations (MPS2) et 6) la somme de la douleur mécanique
après 10 stimulations (MPS10) ont augmenté sur le côté traité à la capsaïne, ce qui suggère
une augmentation de la douleur mécanique (p < 0,002). Le CDT, le CPT et le HPT ont démontré
des effets comparables dans les six centres, le CPT et le HPT démontrant la meilleure
sensibilité. Les données des patients ont révélé une différence significative entre le côté
affecté et le non côté non affecté, mais seulement dans le cas du CDT.
Conclusion: Ces résultats soutiennent l’application de tests sensoriels quantitatifs dans les
études multicentriques portant sur les réponses normales et pathologiques à la douleur.
Introduction
Quantitative sensory testing (QST) has become a valu-
able psychophysical tool to assess pain in mechanistic
studies in healthy volunteers,1–3 clinical studies for
diagnostic purposes,4,5 and pharmacological studies
for the efficacy of analgesic compounds.6,7 QST evalu-
ates the integrity of pain pathways and mechanisms by
identifying alteration or impairment of the somatosen-
sory system,8,9 whereby results may be compared
between individuals or areas within one individual
(affected versus control body parts).
The use of QST in multicenter studies has been quite
limited so far due in part to various methodological
differences and lack of standardized procedures, mea-
sures, and equipment among centers.1,10–12 It is there-
fore essential to minimize these limiting factors in order
to achieve high quality standards for comparability
among centers. In 2006, the German Research Network
on Neuropathic Pain published a comprehensive proto-
col to be reproduced among centers performing clinical
trials. The protocol, consisting of seven tests examining
13 QST parameters, allowed for a complete somatosen-
sory phenotyping of a subject within 1 h for two sym-
metrical body areas.3 This protocol was used to conduct
a nationwide multicenter trial to establish age- and gen-
der-matched absolute and relative QST reference values
from 180 healthy subjects, to be used as control values in
the assessment of patients with neuropathic pain.3
Neuropathic pain-like responses are frequently
assessed in human experimental pain models. Topical
capsaicin has been previously used for assessing therapeu-
tic efficacy of analgesics by producing a unilateral effect
on healthy subjects.13–17 Topical capsaicin application has
proven to be useful to sensitize peripheral nociceptors
specialized in detecting unpleasant noxious stimuli.18
This experimental model is reliable to assess differences
in pain sensitivity among individuals.17 However, the use
of QST employing the capsaicin pain model in multi-
center studies has not been reported and would allow
comparison of findings when used as a surrogate experi-
mental human model of neuropathic pain.
The present study aimed to assess the application of
the capsaicin pain model as a surrogate experimental
human model of neuropathic pain in different centers
and estimate the variation in reports of QST measures
across centers. Additionally, the QST protocol was con-
ducted in patients diagnosed with neuropathic pain. This
comparison of findings in patients and healthy subjects
was intended to consider the clinical relevance of the
topical capsaicin model. This project was performed as
an initiative of the Quebec Pain Research Network.
Material and methods
The initiative of theQuebec Pain ResearchNetwork aiming
at formulating QST guidelines began in 2009. In total, six
independent laboratories with expertise in QST and one
pain clinic took part in the study across four academic
institutions (McGill University, Laval University,
Montreal University, Sherbrooke University). Data collec-
tion occurred between 2011 and 2012. The study protocol
was approved by the institutional ethics committees of all
participating centers prior to the beginning of the study.
Consent forms were signed by participants prior to the
beginning of testing.
Subjects
In six laboratories, ten pain-free subjects (five women,
five men) were recruited and completed testing, for a
total of 60 healthy subjects. Inclusion criteria consisted
of healthy subjects aged 18 to 75 years old who had the
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ability to adequately understand and respond in English
or French. Healthy subjects did not have any history of
migraine, chronic pain, neurological disorders (such as
traumatic brain injury, stroke, epilepsy, encephalopa-
thy), degenerative disorders (Alzheimer’s, Parkinson’s),
should not have taken any medication affecting vigi-
lance, should not have worked in the health care system
or with people suffering from pain, and should not
have previously participated in a study in any of the
participating laboratories.
Twenty patients diagnosed with chronic neuro-
pathic pain were recruited from a tertiary pain clinic
(Alan Edwards Pain Management Unit, Montreal,
Quebec) and completed the protocol (seven women,
13 men). Inclusion criteria consisted of medically
confirmed diagnosis of chronic neuropathic pain,
aged 18 to 75 years old, with proficiency in English
or French and capable of reading and giving written
informed consent. Excluded from the study were
patients for whom the etiology of chronic pain was
not neuropathic and patients who had active cancer.
Diagnoses of neuropathic pain included idiopathic
neuropathic pain (peripheral asymmetric polyneuro-
pathy), peripheral nerve damage or injury, syringo-
myelia, trigeminal neuralgia, ilioinguinal neuropathy,
as well as cervical and thoracic radiculopathy. Among
the 20 patients, 19 had unilateral pain symptoms and
one patient diagnosed with cervical myelopathy had
bilateral pain.
Experimental procedures
Testing and control areas
For the healthy volunteers, using a pen with washable
ink, a 3 × 3 cm area was marked on both forearms at
the midpoint between the crease of the elbow and the
wrist to ensure that testing across all measurements was
performed on the same skin area. On the nondominant
forearm of healthy participants, a thick layer of com-
mercially available odor-free 0.075% capsaicin cream
(CAPZASIN-HP distributed by Chattem) was applied
to this 9 cm2 area to induce sensitization (i.e., the
capsaicin-treated side). Capsaicin temporarily sensitizes
the peripheral nociceptors and thus can transiently
induce allodynia and hyperalgesia.16 After 20 min, the
cream was removed and the skin was thoroughly
washed with water. The untreated forearm was used
as the control skin area (i.e., control side).
Patients were tested on a marked 3 × 3 cm skin area
where pain was reported as being the most intense or
interfered most with daily life (i.e., affected side).
Capsaicin was not applied to patients. The skin area
corresponding to the contralateral body location con-
sisted of the control skin area (i.e., unaffected side).
Quantitative sensory testing
The room temperature was kept between 20°C to 24°C
during testing. A training session including each site
experimenter responsible for administering the proto-
col was conducted by one of the QST experts trained in
Germany (University of Mainz, University of
Heidelberg). Several supervised practice sessions to
master the administration of all tests, including stan-
dardization of all verbal instructions, took place prior
to the beginning of the study. The protocol was mod-
ified from the skin and muscle sensitivity testing pro-
cedures described in 2006 by the German Neuropathic
Pain Study Group.3 Tests were chosen and instructions
were developed based on those used by the German
group and modified by consensus among the investi-
gators of the present study. Our modified QST protocol
included ten parameters providing a comprehensive
profile of somatosensory functions assessed with ther-
mal and mechanical procedures. The material and
equipment used were standardized across all study cen-
ters. Each test was performed on each side for every
participant, always starting on the control or unaffected
skin area, followed by testing on the capsaicin-treated
or painful skin. For all parameters, the mean of three
consecutive measurements on each side was calculated.
Thermal stimulations
Thermal testing started with the cold detection thresh-
old (CDT), followed by the warm detection threshold
(WDT), the cold pain threshold (CPT), and, finally, the
heat pain threshold (HPT). Thermal thresholds were
measured using a 3 × 3 cm probe connected to the TSA
2001-II or a Pathway CHEPS apparatus (Medoc, Israel)
and reported in degrees Celsius. All baseline tempera-
tures (t°) were initially set to 32°C and programmed to
gradually increase or decrease at a rate of 0.5 or 1°C/s,
depending on the test performed. Once the baseline
temperature was perceived as neutral by the participant
(i.e., it was described as neither warm nor cold), the
thermal testing commenced.
Mechanical stimulations
Mechanical detection threshold (MDT) was assessed
using standardized von Frey filaments (Touch-Test
Sensory Evaluators) and data were reported in grams.
Dynamic mechanical allodynia (DMA) for light touch
was assessed with a standardized brush (Somedic
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SENSELab, Brush-05), and numerical pain intensity
scores were reported directly by subjects with the use
of a visual analog scale (scale of 0–200 with 0 indicating
no pain and 200 indicating intolerable pain). On this
scale, the score of 100 marks the limit between a strong
sensation and a painful sensation.19 Mechanical pain
summation with pinprick stimuli was assessed after two
and ten stimulations (MPS2 and MPS10) with the
Neuropen (Owen Mumford) with disposable
Neurotips, and pain intensity was reported with the
use of a visual analog scale (range 0–200). Vibration
detection threshold (VDT) was assessed with the 64-Hz
Rydel-Seiffer graded tuning fork applied to the skin.
Pressure pain threshold (PPT) was assessed using the
JTech Medical USA or Wagner manual algometer.
Thresholds were reported in kilograms.
Statistical analysis
Descriptive data were obtained for age, gender, tested
side, and study center. For healthy subjects, differences
between control (C) and capsaicin-treated (T) sides
were assessed with the use of repeated measures ana-
lyses of variance (ANOVAs) with testing center and
gender as between-subject co-variates. Prior to repeated
measures ANOVAs, normality of variables was evalu-
ated with the Kolmogorov-Smirnov test, and the fol-
lowing logarithmic transformation was applied for
variables without normal distribution: for CDT ln
[(max + 1) − CDT] and for MDT and DMA ln(variable
+ 1). Transformed data obtained a normal distribution.
Effect sizes were calculated in the repeated measures
ANOVAs models for tested sides. For QST variables
where differences between control and capsaicin-trea-
ted sides were found to be significant in the repeated
measures ANOVAs (effect of side), the proportion of
subjects with similar response patterns for both tested
sides (C and T) were examined.
Principal component analysis extracted from a cor-
relation matrix was used to describe the variance struc-
ture of the tests with a significant effect of side. The
analysis was performed on the differences between con-
trol and capsaicin-treated sides corrected for gender
and testing center effects. If original data were nonnor-
mally distributed, the difference was calculated between
the two transformed variables.
Finally, repeated measures ANOVAs were also per-
formed for data obtained in neuropathic pain patients.
Those ANOVAs were composed of only two factors:
(1) body side and (2) gender (note that all patients were
recruited at a single site). P values less than 0.05 were
considered statistically significant. Data are presented
as mean ± standard deviation (SD) and deltas between
control and capsaicin-treated sides. Statistical analysis
was performed with SPSS software.
Results
Study participants
In all laboratories assessing healthy participants (iden-
tified as centers A to F), five female and five male
participants were recruited. The mean ages (±SD) at
each center were 21 ± 3.12, 22 ± 2.97, 23 ± 2.00,
23 ± 3.40, 22 ± 3.37, and 24 ± 4.49, for a global mean
of 23.1 ± 5.1 years. The majority of participants
reported having no pain at the time of testing, although
three subjects reported presence of mild pain on the
day of testing. No medical conditions were reported in
any laboratory. One subject from center B had to stop
the MPS10 assessment due to intolerable pain caused
by the test. Results for this QST parameter are therefore
reported for 59 subjects instead of 60.
The mean age for patients diagnosed with neuro-
pathic pain (center G) was 54.0 ± 9.8 years. One patient
with neuropathic pain had to stop the MPS2 and
MPS10 measurements on the affected body side.
Results for MPS2 and MPS10 are therefore reported
for 19 patients instead of 20.
Experimental procedures
A significant difference was observed in the mean time
required to perform the entire protocol across the labora-
tories ranging from 59 to 73 min (F = 16.5, P < 0.001).
QST measurements in healthy subjects
Thermal stimulations—Capsaicin effect
Significant differences were observed between the mean
responses of the capsaicin-treated and control sides in
three out of four thermal QST parameters (CDT, CPT,
HPT; Table 1). The capsaicin-treated side showed
reduced sensitivity to cool and cold pain (i.e., lower
temperatures for CDT and CPT). In contrast, increased
sensitivity was found to heat pain (lower HPT) and no
significant effect was found for WDT.
Thermal stimulations—Testing center effect
Across the six testing centers, mean values of the cap-
saicin-treated and control sides were comparable for
CDT, WDT, CPT, HPT, and MDT (Ps > 0.05,
Table 1, Figure 1). The HPT was the most robust
QST parameter measured with the lowest variability
among all measures collected across all testing centers.
When considering the difference between body sides
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tested (delta between control and capsaicin-treated), a
significant difference was observed in ΔCDT among
centers (P = 0.029), with one testing center reporting
greater threshold values for the capsaicin-treated side.
Other QST parameters did not show differences for the
delta values across the centers (WDT, CPT, HPT).
Mechanical stimulations—Capsaicin effect
Three QST parameters were able to detect a significant
difference between the capsaicin-treated and control
body sides (Table 1). For MDT and DMA, the mean
values were nonnormally distributed and a logarithmic
[ln (variableþ 1)] transformation was performed to
reduce skewness. Dynamic mechanical allodynia was
significantly higher in the capsaicin-treated side com-
pared to the control side (P = 0.002), indicating a
greater pain sensitivity to brush-evoked pain on the
capsaicin-treated side. Mechanical pain summation
was illustrated by increased sensitivity in the capsai-
cin-treated skin after two (MPS2; P < 0.001) and ten
(MPS10; P < 0.001) pinprick stimuli (Table 1). No
differences were observed between sides for MDT,
VDT, and PPT (all Ps > 0.05).
Mechanical stimulations—Testing center effect
Converse to thermal stimulation tests, the mechanical
stimulation tests showed significant differences in the
mean values between the six testing centers for DMA
Figure 1. Thermal stimulation thresholds determined in six independent laboratories for capsaicin-treated and control sides of
healthy subjects for (A) cold detection threshold; (B) warm detection threshold; (C) cold pain threshold; and (D) heat pain threshold.
Data are presented as means ± standard errors of the mean of absolute temperature thresholds in degrees Celsius.
Table 1. Repeated measure ANOVAs assessing effects of capsaicin-treated vs. control skin in healthy subjects for QST parameters
with center and gender as confounders.
CDTa WDT CPT HPT MDTb DMAb MPS2 MPS10 VDT PPT
ANOVA factor (P values)
Healthy subjects (n) 60 60 59c 60 59c 60 60 59c 60 60
Side (C vs. T) <0.001 0.211 <0.001 <0.001 0.361 0.002 <0.001 <0.001 0.520 0.480
Gender 0.054 0.004 0.827 0.065 0.084 0.646 0.662 0.384 0.683 0.202
Center 0.130 0.102 0.411 0.217 0.200 0.003 <0.001 <0.001 <0.001 <0.001
Side × Gender 0.553 0.473 0.162 0.641 0.027 0.386 0.727 0.223 0.982 0.675
Side × Center 0.029 0.409 0.895 0.376 0.552 0.202 0.869 0.016 0.641 0.759
Effect size (C vs. T) 0.405 0.029 0.185 0.793 0.016 0.170 0.359 0.298 0.008 0.013
aln[(max + 1) − CDT] transformation.
bln(variableþ 1) transformation.
cOne subject could not tolerate the test under that modality; see Materials and Method section.
ANOVA = analysis of variance; QST = quantitative sensory testing; CDT = cold detection threshold; WDT = warm detection threshold; CPT = cold pain
threshold; HPT = heat pain threshold; MDT = mechanical detection threshold; DMA = dynamic mechanical allodynia; MPS2 = mechanical pain summation
after two stimuli; MPS10 = mechanical pain summation after ten stimuli; VDT = vibration detection threshold; PPT = pressure pain threshold; C = control; T
= capsaicin-treated.
270 C. E. FERLAND ET AL.
(P < 0.003), MPS (after both two and ten stimuli;
P < 0.001), VDT (P < 0.001), and PPT (P < 0.001;
Figure 2). When considering the difference between
sides tested (delta between control and capsaicin-trea-
ted), a significant difference (P = 0.016) was observed
among testing centers in the MPS10 deltas for testing
sites A–F (Table 1).
Although no statistically significant differences
were observed among all sites for MDT (P = 0.200),
one center reported opposite results from all other
Figure 2. Mechanical stimulation thresholds determined in six independent laboratories (centers A to F) for capsaicin-treated and
control sides of healthy subjects for (A) mechanical detection threshold; (B) dynamic mechanical allodynia; (C) mechanical pain
summation (two stimulations); (D) mechanical pain summation (ten stimulations); (E) vibration detection threshold; and (F) pain
pressure threshold. Data are presented as absolute threshold means ± standard errors of the mean.
CANADIAN JOURNAL OF PAIN/REVUE CANADIENNE DE LA DOULEUR 271
centers with higher detection thresholds on the con-
trol body side (delta between control and capsaicin-
treated of 0.02 at site B), when all other centers
reported higher thresholds on the capsaicin-treated
body side (Figure 2A). When testing for DMA, sig-
nificant differences were observed in pain intensity
reported by subjects between testing centers, with
five centers reporting hyperalgesia on the capsaicin-
treated skin, whereas one center reported hypoalgesia
(site D; Figure 2B). Less variability among deltas was
observed for the MPS2 parameter (Figure 2C) and
MPS10 (Figure 2D), although again one center
reported reverse results compared to the other testing
centers.
Control and capsaicin-treated QST parameter
response patterns
The results revealed differences in the parameter
responses among the healthy subjects tested
(Table 2). In fact, absolute threshold temperatures
for CDT were lower on the capsaicin-treated side in
80% of subjects; that is, there was a reduced sensitiv-
ity to cool on the capsaicin-treated side compared to
the control side, whereas 20% of healthy subjects had
higher absolute threshold temperatures for CDT on
the capsaicin-treated side, indicating an increased
sensitivity to cool on the capsaicin-treated side.
CPT values were reported to be lower in the majority
of subjects (69.5%) on the capsaicin-treated side—
that is, a decreased sensitivity to cold pain—although
some subjects reported higher thresholds on the cap-
saicin-treated side (25.4%)—that is, an increased sen-
sitivity to cold pain—and three subjects (5.1%) had
similar values on both tested sides. HPT response
patterns (control vs. capsaicin-treated) between both
sides were similar for almost all subjects (96.7% had
lower absolute temperature thresholds for HPT on
the capsaicin-treated side, indicating an increased
sensitivity to heat pain), with only two subjects out
of 60 having higher HPT on the capsaicin-treated
side; that is, a decreased sensitivity to heat pain.
More variability in the response patterns was
observed for the mechanical parameters, and higher
sensitivity was reported on the capsaicin-treated body
side for allodynia and pain summation (MPS).
We performed a principal component analysis of the
six sensory tests that were significantly different
between the control and capsaicin-treated sides in
healthy subjects in order to investigate whether there
was a pattern in the sensory profiles (Table 3). Among
the original six variables, 33% of the total variance was
explained by MPS2, MPS10, and DMA (component 1
of the principal component analysis). A strong associa-
tion between these three tests was observed, suggesting
that the three tests vary together. If MPS2 detects a
strong difference between the control body side vs.
the capsaicin-treated body side, MPS10 and DMA will
likely differ as well between the two sides. CDT and
CPT vary together (component 2), whereas HPT does
not correlate with any of the original five sensory tests
and by itself contributes 16.4% of total variance (com-
ponent 3).
Chronic neuropathic pain patients
When assessing the difference between the affected and
unaffected body sides of patients, the test to evaluate
sensitivity to cold demonstrated reduced sensitivity
(i.e., higher detection thresholds) on the affected body
side with temperature values of 25 ± 8.3°C compared to
29 ± 2.0°C for the unaffected side (P = 0.022; Table 4).
The CDT was the only parameter tested that was able
to detect a significant difference between the affected
and the unaffected body side (P = 0.022, effect size:
0.258).
Table 2. Proportion of healthy subjects and percentage of the
total cohort with increased or decreased absolute threshold
values in the capsaicin-treated body side in relation to the
control body sides.a
Variable C > T C < T C = T n
CDT 48 (80.0) 12 (20.0) 0 (0.0) 60
CPT 41 (69.5) 15 (25.4) 3 (5.1) 59
HPT 58 (96.7) 2 (3.3) 0 (0.0) 60
DMA 16 (26.7) 36 (60.0) 8 (13.3) 60
MPS2 15 (25.0) 43 (71.7) 2 (3.3) 60
MPS10 16 (27.1) 39 (66.1) 4 (6.8) 59
aData are presented as n (%).
C = control; T = capsaicin-treated; CDT = cold detection threshold; CPT =
cold pain threshold; HPT = heat pain threshold; DMA = dynamic mechan-
ical allodynia; MPS2 = mechanical pain summation after two stimuli;
MPS10 = mechanical pain summation after ten stimuli.
Table 3. Principal component analysis on the difference between
the control vs. capsaicin-treated body sides (Delta (C − T)) of the six
QST parameters that could detect a significant difference between C
vs. T for healthy subjects (variables are corrected for site and gender
effects).
Variable
Component
1
Component
2
Component
3
Delta (C − T) MPS2 0.787 0.182 0.304
Delta (C − T) MPS10 0.766 0.195 0.074
Delta (C − T) lnCDT −0.256 0.810 0.159
Delta (C − T) CPT 0.523 −0.633 −0.060
Delta (C − T) HPT −0.226 −0.248 0.926
Delta (C − T) lnDMA 0.636 0.298 −0.023
Proportion of variability of
each component (%)
33.3 21.3 16.4
C = control; T = capsaicin-treated; QST = quantitative sensory testing; MPS2
= mechanical pain summation after two stimuli; MPS10 = mechanical
pain summation after ten stimuli; CDT = cold detection threshold; HPT =
heat pain threshold; DMA = dynamic mechanical allodynia.
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Participants versus patients
Figures 3 and 4 illustrate the interindividual patterns by
demonstrating parameter deltas (difference in the abso-
lute threshold values) for the healthy subjects (control,
capsaicin-treated skin) and deltas for the chronic neu-
ropathic pain patients (control, affected skin). The rela-
tive proportion of healthy participants and neuropathic
pain patients reporting the opposite pattern to the
majority is very similar, with the exception of HPT
and CPT.
Discussion
Following a standard training session for the QST pro-
tocol, the capsaicin model was successfully implemented
in six different participating centers. In our study, six out
of nine QST measures detected a statistically significant
difference between the capsaicin-treated and control
body sides (CDT, CPT, HPT, DMA, MPS2, and
MPS10). Among these, three were reproducible (CDT,
CPT, and HPT) across the six testing centers. Thirty-
three percent of the total variance of the difference
between capsaicin-treated and control skin was
explained by DMA and MPS, whereas HPT did not
correlate with any of the other five sensory tests and
uniquely explained 16.4% of the total variance. When
considering the effect of testing center on capsaicin
effects, only CPT and HPT were capable of detecting
comparable differences between capsaicin-treated versus
control sides across all testing sites. When assessing the
same parameters in patients with chronic neuropathic
pain, only CDT was significantly different between the
two tested sides at the group level, with lower tempera-
tures needed to be perceived at the affected side.
Abnormalities in somatosensory perception, includ-
ing gain or loss of sensory function to thermal and/or
mechanical stimuli, are frequent complaints of patients
with peripheral neuropathies.20–22 In our study, the
majority of healthy subjects reported hypoesthesia to
cold stimulation on the capsaicin-treated skin in com-
parison to the control skin, which is a common symp-
tom reported by patients with neuropathic pain21,23 and
was also observed when testing with patients suffering
from neuropathic pain in this study. However, when
assessing pain sensitivity, we observed different pat-
terns of sensory changes assessed by QST in healthy
subjects and patients with neuropathic pain, although
we did not perform a direct comparison between the
QST measures of healthy subjects and patients with
neuropathic pain due to a small sample size and differ-
ences in population source. A large proportion of our
healthy subjects displayed an increased threshold (i.e.,
lower temperature) to cold-induced pain, suggesting
cold hypoalgesia, whereas a lower cold pain threshold
(i.e., higher temperature) has been reported in patients
with unilateral neuropathy.20,23 Enax-Krumova and
colleagues also reported a paradoxical capsaicin cold
hypoalgesia.24 As they reported, we also expected
signs of sensitization from capsaicin but also observed
cold hypoalgesia, as in patients suffering from neuro-
pathic pain. This concomitant phenomenon can be
explained by the fact that the stimulation that was
supposed to be on the primary zone was slightly offset
and reached the secondary zone where sensitization has
been reported in other studies.25,26 Several mechanisms
could be responsible for this hyposensitivity, including
the selective excitation of capsaicin-sensitive C fiber
nociceptors likely leading to a selective spinal inhibition
of mechanoreceptive nerve fibers.26
Nearly all healthy subjects showed increased pain
sensitivity to heat stimuli, revealing the presence of
thermal allodynia on their capsaicin-treated skin.
Although heat hyperalgesia is found in patients with
peripheral nerve injury, a larger proportion of patients
show heat hypoalgesia.23 When applied to the skin,
capsaicin triggers vesicular release of pro-nociceptive
peptides in the periphery, leading to neurogenic
Table 4. ANOVA and effect sizes comparing affected vs. non-affected sides and gender for different QST parameters in chronic
neuropathic pain patients.
CDTa WDT CPT HPT MDTb DMAb MPS2 MPS10 VDT PPT
ANOVA factor
Patients (n) 20 20 20 20 18 20 19 20 20 20
Side (affected vs. non-affected) 0.022 0.261 0.951 0.738 0.948 0.460 0.290 0.610 0.990 0.507
Gender 0.924 0.689 0.189 0.422 0.327 0.724 0.435 0.741 0.056 0.522
Side × Gender 0.513 0.763 0.424 0.756 0.897 0.331 0.693 0.318 0.730 0.478
Effect size 0.258 0.070 <0.001 0.006 <0.001 0.031 0.066 0.015 <0.001 0.025
aln[(max + 1) − CDT] transformation.
bln(variableþ 1) transformation.
ANOVA = analysis of variance; QST = quantitative sensory testing; CDT = cold detection threshold; WDT = warm detection threshold; CPT = cold pain
threshold; HPT = heat pain threshold; MDT = mechanical detection threshold; DMA = dynamic mechanical allodynia; MPS2 = mechanical pain summation
after two stimuli; MPS10 = mechanical pain summation after ten stimuli; VDT = vibration detection threshold; PPT = pressure pain threshold.
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Figure 3. Interindividual patterns of thermal parameter results determined in six independent laboratories for control and capsaicin-
treated skin in healthy subjects (n = 60) and control and affected skin for patients with chronic neuropathic pain (n = 20) for (A), (B)
cold detection threshold, (C), (D) cold pain threshold, and (E), (F) heat pain threshold. Deltas of absolute values (control, capsaicin-
treated skin) are presented for the healthy subjects and deltas (control, affected skin) are presented for patients with neuropathic
pain. The direction of change (gain/loss of sensitivity) according to a positive or negative delta is indicated on the Y-axis.
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Figure 4. Interindividual patterns of mechanical parameter results determined in six independent laboratories for non-affected
(control) and capsaicin-treated (treated) skin in healthy subjects (n = 60) and for control and affected skin in patients with chronic
neuropathic pain (n = 20) for (A), (B) dynamic mechanical allodynia and mechanical pain summation after (C), (D) two stimuli and (E),
(F) ten stimuli. Deltas of absolute values (control, capsaicin-treated skin) are presented for the healthy subjects and deltas (control,
affected skin) are presented for patients with neuropathic pain. The direction of change (gain/loss of sensitivity) according to a
positive or negative delta is indicated on the Y-axis.
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inflammatory response.27 It is therefore not surprising
that capsaicin induced an increased sensitivity to heat
but not to cold, which is similar to inflammation.
Among the six sensory tests that differentiated capsai-
cin-treated from control skin, we observed a pattern of
variation where certain tests seemed to be associated with
each other and thus varied together. Cold sensitivity is
mediated by A-delta and C fibers8,28 and when the tests
yield measures corresponding to hypoesthesia, it is
thought to be due to deafferentation.8,28,29 Capsaicin pro-
duces an initial algesic effect prior to the known reversible
anti-nociceptive and anti-inflammatory actions.30 It
seems that our results demonstrate the primary transient
effects of topical capsaicin involving the vanilloid receptor
subtype 1 activation on A-delta and C fibers. Although
our healthy subjects did not have any nerve deafferenta-
tion, topical capsaicin produces temporary loss of cold
sensitivity, yielding results for CDT and CPT similar to
the sensory profile of patients with neuropathic pain with
deafferentation.17 Similar to CPT, MPS measures the
function of both A-delta and C fibers.8,28 The mechanism
underlying temporal summation to pinprick stimuli
(MPS10), as observed in the majority of subjects when
comparing the capsaicin-treated body side to the control
body side, is postulated to reflect central sensitization.28,31
Similarly, central sensitization is thought to be the neu-
rophysiological process responsible for DMA.32–36 The
fact that DMA and temporal summation to pinprick
stimuli varied together suggests that the central phenom-
ena of both measures are closely related. Similar to cold
sensitivity, HPT tests the function of A-delta and C
fibers.8,28 In contrast to the reduction in cold sensitivity,
however, the majority of our subjects displayed heat
hyperalgesia, indicating peripheral sensitization rather
than deafferentation.8,28,29 This suggests that subpopula-
tions of A-delta and C fibers were differently affected by
capsaicin application. In support of this notion, differ-
ences in HPT between capsaicin and control skin did not
co-vary with differences in CDT and CPT.
Capsaicin is a frequently used model to target pain
therapies.37 However, whether capsaicin does reproduce
a specific neuropathic-like sensory pattern is still under
debate.38 The differential effects of capsaicin on the skin is
dependent on the dose, duration, and frequency of appli-
cation, possibly explaining how it can be both a therapeu-
tic agent for pain as well as an experimental model of pain
and in part how our QST results in healthy subjects did
not entirely reproduce the sensory effects seen in Simone
and Ochoa’s study.39 It has been used as an experimental
model of neuropathic pain17,37,40 as well as a model of
acute inflammation.38,41,42 Neuropathic pain is defined as
pain caused by a lesion or disease of the central or per-
ipheral nervous system.22,43,44 Therefore, it seems unlikely
that capsaicin may accurately reproduce sensory abnorm-
alities like those experienced by neuropathic pain patients,
and its use as a surrogate model for neuropathic pain
should be carefully considered. Capsaicin-induced irrita-
tion causes superficial dermal inflammation from an acti-
vation of vanilloid receptor subtype 1 receptors that is
then conveyed through pain pathways, suggesting noci-
ceptive pain rather than neuropathic pain.44 This noci-
ceptive aspect of capsaicin may explain why we were
unable to observe differences in some of the QST para-
meters, three of which were mechanical stimulations. If
capsaicin only produces a topical nociceptive response, it
then seems unsurprising that VDT and PPT were not
discriminating between the capsaicin-treated and
untreated body sides.
There was large variability observed in the interindi-
vidual results, suggesting that individuals react differ-
ently to topical capsaicin. In their study of healthy
subjects, Lötsch et al. found that capsaicin induced a
pain-like reaction similar to neuropathy in only 18% of
their cohort (n = 110).17 This may explain the varia-
bility found in our study, specifically for CPT, where a
significant proportion (25%) of the tested subjects
reported lower pain sensitivity on their capsaicin-trea-
ted side. Therefore, capsaicin sensitivity prescreening
test, as suggested by Lötsch et al., should occur prior to
the actual experimental testing to ensure homogeneity
in capsaicin sensitivity among study subjects.17
In line with the conclusions of the German Research
Network on Neuropathic Pain,8 one of the strengths of
this study was determining the gain or loss of somato-
sensory function by comparing an affected side (cap-
saicin-treated side in healthy subjects or painful side in
patients) with its contralateral unaffected body side.
This methodological approach contributes to eliminat-
ing some of the interindividual variance, providing a
more accurate comparison between affected and unaf-
fected body sides.
Certain limitations are worth noting. The lack of
power may have caused missed discrimination between
tested sides ormay have causedmissed differences among
testing centers. Various studies have investigated the
reliability and reproducibility of QST parameters in mul-
ticenter studies and have demonstrated their sensitivity to
sensory abnormalities in patients experiencing neuro-
pathic pain, confirming the validity of these tests.21,23 In
our study, for some QST parameters measured, the inter-
individual variability was important enough that no dif-
ferences were reported at the group level. Secondly, in the
patient group, the lack of homogeneity in the syndrome
underlying the neuropathic pain may have caused signifi-
cant differences in the obtained results, because different
neurological syndromes revealed different somatosensory
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profiles.21,45 A limitation of MPS is the choice of instru-
ment used to produce pinprick pain. The shape of the
Neuropen’s tip is both rounded and flat; a flat right-
angled tip may be preferred to evoke pinprick hyperalge-
sia or sharp pain.35 However, it is believed that mechan-
ical pinprick hyperalgesia is a response to stimulation of
mainly A-delta fibers46,47 and this may not be the case
with the Neuropen tip.35 Another potential limitation in
our study was that no test for glucose tolerance was
performed for the healthy participants. Diabetes mellitus
and even impaired glucose tolerance are well-known
causes of peripheral neuropathy.48
Differences between testing centers were observed
for the majority of the assessed parameters, although
a training session regarding the test procedures was
conducted in each testing center. The experimental
design followed recommendations by experts in the
QST field, but the results still indicate some technical
issues. Standardization seems to be more difficult when
the experimenter is responsible for the stimulus (allo-
dynia, summation, vibration, pain pressure), as pre-
viously suggested by Geber et al.1 Multicenter studies
using QST in patients with pain and healthy subjects
have shown poor reproducibility of thermal and
mechanical thresholds.12,49 Furthermore, inconsisten-
cies in acquired results could be attributed to the
multi-examiner effect.1 They concluded that a strict
standardized protocol and a rigorous training of exam-
iners could overcome potential limitations of the multi-
center approach.1 In our study, lab personnel were
trained with a standardized protocol during a session,
but no interobserver reliability was assessed. More
emphasis on standardization of stimuli, instructions to
the subjects, testing algorithms, and reference values
(corrected for anatomical site, age, and gender) in
healthy subjects and in patients are mandatory for
quality multicenter studies.50
Most published studies report mean results for each
group or treatment. However, there is an important varia-
bility between subjects. As shown in Figures 3 and 4, when
plotting the delta between the control skin and the capsai-
cin-treated skin, there is substantial variability in the results
for healthy subjects and patients. The subjects or patients
with the highest and lowest responses most probably have
different endogenous pain modulatory processes and may
respond differently to a specific treatment.51 Taking into
account this interindividual variability may guide the
development of personalized approaches that would be
better suited than approaches based on mean results.
In conclusion, capsaicin is a good experimental pain
model that can be used for multicenter studies but with
several limitations. Major precautions should be
included in the experimental design. When using
capsaicin, some QST thermal procedures provide better
reproducibility across study centers.
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